Applicants:	Monaci, et al.			
	To Be Assigned SUS MONKEY HER2/NEU, NUCLEOT DDING SAME, AND USES THEREOF	IDES	Art Unit: _ Examiner:	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

OPRESS MAIL CERTIFICATE
BATE OF DEPOSIT 7-1-05
EXPRESS MAIL NO. EL 989603865 U.S. HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  HEREBY CERTIFY THAT THE UNITED STATES POSTA
A MERCRY CERTIFY THAT THIS CORRESPONDENCE IS
DOUGH DEUTSCHEIT WHITE LIFE CONTICUISING TO VOICE
SECURE AS EXPOSES MAN WIEST DEPICE IN AUDICISSES
AN THE ARAVE PATE IN AN ENVELUPE ADDRESSED BY
COMMISSIONER FOR PATENTS, P.U. BUX 1436
ALEXANDRIA, PERCUNIA 22313-1450
MONTED BY Kaller & Luthouse
DATE 7-14-09
A THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS N

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

	MERCK	& CO., INC.
By		Date
,		

## JC14 Rec'd T/PTO 01 JUL 2005 INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

not enclosed. Related application(s) in which references were su	ubmitted to or cited by the Office	are as follows:			
	RELATED APPLICATION				
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If this is inconvenient, additional copies will be submitted upon	request.				
6. In accordance with 37 C.F.R. 1.97, (check one)					
$\checkmark$ the attached information is filed within three months of the f	iling date of the captioned case.				

If th	this is inconvenient, additional copies will be submitted upon request.	
	6. In accordance with 37 C.F.R. 1.97, (check one)	
$\checkmark$	the attached information is filed within three months of the filing dat	e of the captioned case.
	the attached information is filed more than three months after the file.  Office Action on the merits.	ling date but prior to the mailing of a first
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Acauthorization is therefore given to charge Deposit Account No. 13-2 1.17(p).	ction or Notice of Allowance. The enclosed
	the undersigned certifies that each item of information contained in cited in any communication from a foreign patent office in a counter months prior to the filing of this Statement.	
	the undersigned certifies that no item of information contained in the a communication from a foreign patent office in a counterpart foreign person signing the certification after making reasonable inquiry, wa C.F.R. 1.56(c) more than three months prior to the filing of this States	n application, and, to the knowledge of the sknown to any individual designated under 37
	ı	Respectfully submitted,
		alizi from _
		By: Alysia A. Finnegan
	<u> </u>	Attorney For Applicant(s)
		Reg. No. <u>48,878</u>
		MERCK & CO., INC. Patent Dept., RY60-30
		P.O. Box 2000
		Rahway, N.J. 07065-0907
	(	(732)594- <u>2583</u>
		Date: 7/1/05

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office: U.S DEPARTMENT OF COMMERCE

	ubstitute for form 1449A/PTO	4		COMPLE F KNOWN			
INFORMATION DISCLOSURE				Application Number	To Be Assigned	10/54127	
COLLA DELL'ACCIONE DAZ. A DIDI ACCIONIO				Filing Date			
2	STATEMENT BY APPLICANT			First Named Inventor	Monaci, et al.		
	,		,	Group Art Unit			
	(use as many sheets as necessary)			Examiner Name			
Sheet	1	of	3	Attorney Docket Number	ITR0043YP		

			U.S. PA	ATENT DOCUMENTS	
Examiner nitials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY
	A	5,846,538		Cheever, et al.	12/08/1998
-	В	5,869,445		Cheever, et al.	02/09/1999
	С	6,127,344		Amici, et al.	10/03/2000
		1			

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent Docume	nt		Date of Publication of			
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
	D	PCT	WO 02/22080 A3		Merck & Co., Inc.	03/21/2002			
•									
			1						

Examiner Signature	Date Considered	

## JC14 Rec'd PCT/PTO 0 1 JUL 2005 Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Private and Technology (Office U.S. DEPARTMENT OF ECONOMICS OF COMPANIES).

		- 400		Patent and Trademark Off	ice; U.S DEPARTMENT OF COMMERCE	
sheriture for form 1440B/BTO			COMPLE F KNOWN			
	DIS	<b>SLOSURE</b>	Application Number	To Be Assigned	10/54127	1
TATEMENT DV	ΑĐ	DI ICANT	Filing Date			9
STATEMENT BY APPLICANT			First Named Inventor	Monaci, et al.		
(			Group Art Unit			
(use as many sneets as necessary)			Examiner Name			
2	of	3	Attorney Docket Number	ITR0043YP		
	TATEMENT BY	NFORMATION DISTATEMENT BY AP  (use as many sheets as n	TATEMENT BY APPLICANT  (use as many sheets as necessary)	Application Number  Filing Date  First Named Inventor  (use as many sheets as necessary)  Figure 14498/PTO  Application Number  Filing Date  First Named Inventor  Group Art Unit  Examiner Name	TATEMENT BY APPLICANT  (use as many sheets as necessary)  COMPLE F Kitch Application Number To Be Assigned Filing Date First Named Inventor Monaci, et al.  Group Art Unit Examiner Name	Application Number  To Be Assigned 10/54/27  Application Number  To Be Assigned 10/54/27  Filing Date  First Named Inventor Monaci, et al.  Group Art Unit  Examiner Name

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	E	Bargmann, et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein", Nature, Vol. 319, 16 January 1986, pp. 226-230.				
	F	Chartier, et al., "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in Escherichia coli", J. of Virology, Vol. 70, No. 7, July 1996, pp. 4805-4810.				
	G	Cheever, et al., "Immunity to Oncogenic Proteins", Immunological Reviews, No. 145, 1995, pp. 33-59.				
	Н	Coussens, et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene", Science, Vol. 230, 6 December 1985, pp. 1132-1139.				
	I	Disis, et al., "Oncogenic proteins as tumor antigens", Current Opinion in Immunology, Vol. 8, 1996, pp. 637-642.				
	J	Disis, et al., "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer", Anvances in Cancer Research, Vol. 71, pp. 343-371, 1997.				
	K	Disis, et al., "Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines", J. of Clin. Oncol., Vol. 20, No. 11, pp. 2624-2632, 2002.				
	L	Disis, et al., "Cancer Vaccines Targeting the Her2/neu Oncogenic Protein", Seminars in Oncology, Vol. 28, No. 6, Suppl.18, pp. 12-20, December 2001.				
	М	Foy, et al., "Vaccination with HER-2/neu DNA or protein subunits protects against growth of a HER-2/neu-expressing murine tumor", Vaccine, Vol. 19, pp. 2598-2606, 2001.				
	N	King, et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma", Science, Vol. 229, pp. 974-976, 1985.				
	0	Lohrisch, et al., "An Overview of HER2", Seminars in Oncology, Vol. 28, No. 6, Suppl 19, December 2001, pp. 3-11.				
-	P	Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination:Optimization of DNA Vectors", DNA and Cell Biology, Vol. 13, No. 9, 777-792, 1993.				
	Q	Press, et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues", Oncogene, Vol. 5, pp. 953-962, 1990.				
	R	Shih, et al., "Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts", Nature, Vol. 290, 19 March 1981, pp. 261-264.				
	s	Shiver, et al., "Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination", Annals New York Academy of Sciences, Vol. 772, pp. 198-208, 1996.				

Examiner Signature	Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003

JC14 Rec°d PCT/PTO 01 JUL 2005
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Su	Substitute for form 1449B/PTO			COMPLE		
I	NFORMATION I	DIS	<b>ELOSURE</b>	Application Number	To Be Assigned	10/54127
STATEMENT BY APPLICANT				Filing Date		
				First Named Inventor	Monaci, et al.	
				Group Art Unit		
	(use as many sheets	as n	ecessary)	Examiner Name		
Sheet	3	of	3	Attorney Docket Number	ITR0043YP	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
	Т	Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer", Science, Vol. 244, pp. 707-712, May 12, 1989.						
	U	Slichenmyer, et al., "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases", Seminars in Oncology, Vol. 28, No. 5, Suppl. 16, October 2001, p. 67-79.						
	v	Yarden, Y. "Biology of HER2 and Its Importance in Breast Cancer", Oncology, Vol. 61 (Suppl 2), 2001, pp. 1-13.						

Examiner Signature	Date Considered	